NASDAQ:MEDP - Nasdaq - US58506Q1094 - Common Stock - Currency: USD
305.11
+2.86 (+0.95%)
The current stock price of MEDP is 305.11 USD. In the past month the price increased by 0.33%. In the past year, price decreased by -22.28%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 19.34 | 159.89B | ||
DHR | DANAHER CORP | 26.72 | 142.45B | ||
A | AGILENT TECHNOLOGIES INC | 20.46 | 30.97B | ||
IQV | IQVIA HOLDINGS INC | 13.78 | 27.06B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 27.19 | 22.92B | ||
WAT | WATERS CORP | 29.52 | 20.85B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.82 | 15.18B | ||
ILMN | ILLUMINA INC | 31.79 | 12.33B | ||
ICLR | ICON PLC | 10.42 | 11.80B | ||
RVTY | REVVITY INC | 19.06 | 11.29B | ||
TEM | TEMPUS AI INC | N/A | 9.87B | ||
QGEN | QIAGEN N.V. | 19.52 | 9.32B |
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 5,900 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
MEDPACE HOLDINGS INC
5375 Medpace Way
Cincinnati OHIO 45227 US
CEO: August J. Troendle
Employees: 5900
Phone: 15135799911
The current stock price of MEDP is 305.11 USD. The price increased by 0.95% in the last trading session.
The exchange symbol of MEDPACE HOLDINGS INC is MEDP and it is listed on the Nasdaq exchange.
MEDP stock is listed on the Nasdaq exchange.
17 analysts have analysed MEDP and the average price target is 313.07 USD. This implies a price increase of 2.61% is expected in the next year compared to the current price of 305.11. Check the MEDPACE HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MEDPACE HOLDINGS INC (MEDP) has a market capitalization of 9.10B USD. This makes MEDP a Mid Cap stock.
MEDPACE HOLDINGS INC (MEDP) currently has 5900 employees.
MEDPACE HOLDINGS INC (MEDP) has a support level at 290.15 and a resistance level at 305.12. Check the full technical report for a detailed analysis of MEDP support and resistance levels.
The Revenue of MEDPACE HOLDINGS INC (MEDP) is expected to grow by 3.4% in the next year. Check the estimates tab for more information on the MEDP EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MEDP does not pay a dividend.
MEDPACE HOLDINGS INC (MEDP) will report earnings on 2025-07-21, after the market close.
The PE ratio for MEDPACE HOLDINGS INC (MEDP) is 23.29. This is based on the reported non-GAAP earnings per share of 13.1 and the current share price of 305.11 USD. Check the full fundamental report for a full analysis of the valuation metrics for MEDP.
The outstanding short interest for MEDPACE HOLDINGS INC (MEDP) is 8.51% of its float. Check the ownership tab for more information on the MEDP short interest.
ChartMill assigns a technical rating of 1 / 10 to MEDP. When comparing the yearly performance of all stocks, MEDP is a bad performer in the overall market: 76.24% of all stocks are doing better.
ChartMill assigns a fundamental rating of 7 / 10 to MEDP. MEDP gets an excellent profitability rating and is at the same time showing great financial health properties.
Over the last trailing twelve months MEDP reported a non-GAAP Earnings per Share(EPS) of 13.1. The EPS increased by 33.54% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 19.31% | ||
ROA | 21.95% | ||
ROE | 70.14% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 74% to MEDP. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -0.92% and a revenue growth 3.4% for MEDP